IMMUNOHISTOCHEMISTRY, ALKD5F3

The Immunohistochemistry (IHC) – ALK D5F3 test is a highly specialized diagnostic test used to detect Anaplastic Lymphoma Kinase (ALK) protein expression in tissue samples. The D5F3 antibody clone is widely recognized for its high sensitivity and accuracy in identifying ALK-positive tumors, particularly in non-small cell lung cancer (NSCLC) and certain lymphomas.

ALK is a gene that can become abnormally rearranged or fused with other genes, causing uncontrolled cell growth and cancer development. Detecting ALK protein expression is critical because ALK-positive cancers often respond well to targeted therapies such as ALK inhibitors, which can significantly improve treatment outcomes.

The ALK D5F3 test is commonly used in the diagnosis and classification of:

• ALK-positive non-small cell lung carcinoma
• Anaplastic large cell lymphoma (ALCL)
• Inflammatory myofibroblastic tumors
• Certain rare soft tissue tumors

The D5F3 clone is considered one of the most reliable methods for screening ALK rearrangements and is often used as a first-line diagnostic tool before molecular confirmation if needed.

Benefits of the Test

The ALK D5F3 test offers several important clinical benefits:

• Detects ALK protein expression accurately
• Identifies ALK-positive cancers
• Helps guide targeted therapy selection
• Supports precise tumor classification
• Improves treatment personalization
• Provides prognostic and therapeutic insights

This test is essential for precision oncology.

Why Doctors Recommend This Test

Doctors recommend the ALK D5F3 test when ALK-positive cancer is suspected.

It is commonly advised for:

• Newly diagnosed non-small cell lung cancer
• Suspected ALK-positive lymphoma
• Evaluation of inflammatory myofibroblastic tumors
• Advanced molecular tumor profiling
• Targeted therapy eligibility assessment

The results help oncologists identify patients who may benefit from ALK inhibitor treatment.

Preparation Before Test

No special preparation is required from the patient. The test is performed on previously collected tissue biopsy or surgical specimens.

Normal Reporting Time

The usual turnaround time for the ALK D5F3 IHC test is 3 to 5 working days, depending on tissue complexity and laboratory workflow.

Who Should Take This Test

This test is recommended for:

• Patients diagnosed with non-small cell lung cancer
• Individuals suspected of ALK-positive tumors
• Patients requiring molecular tumor classification
• Cases needing targeted therapy evaluation
• Oncology patients requiring precision treatment planning

The IHC ALK D5F3 test is an essential diagnostic tool in modern oncology. It accurately detects ALK-positive cancers and helps guide personalized targeted therapy for improved survival and treatment success.